Natera, Inc. (NASDAQ:NTRA) Receives $267.83 Consensus Price Target from Brokerages

Shares of Natera, Inc. (NASDAQ:NTRA) have earned an average rating of “Moderate Buy” from the twenty-two brokerages that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, fourteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $267.8333.

A number of equities analysts have issued reports on the company. Zacks Research downgraded Natera from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Guggenheim increased their price objective on Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Natera in a report on Monday, July 6th. Piper Sandler restated an “overweight” rating and issued a $249.00 target price on shares of Natera in a report on Tuesday, May 12th. Finally, BTIG Research set a $275.00 target price on Natera and gave the company a “buy” rating in a research report on Wednesday, June 24th.

Natera Price Performance

NASDAQ:NTRA opened at $253.82 on Monday. The firm has a 50-day moving average of $244.16 and a 200-day moving average of $221.65. The company has a market cap of $36.35 billion, a PE ratio of -155.72 and a beta of 1.51. Natera has a one year low of $131.81 and a one year high of $288.04.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Neutral Sentiment: Most notably, CFO Michael Burkes Brophy sold 5,064 shares for approximately $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for about $1.48 million. Both executives cited pre-arranged Rule 10b5-1 trading plans and said the sales were made to cover tax-withholding obligations related to vested equity awards, reducing the likelihood that the transactions signal a loss of confidence. CFO SEC filing CEO SEC filing
• Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold a combined 3,927 shares worth approximately $1.01 million under similar pre-arranged plans to meet tax obligations. They retained substantial holdings after the sales, further limiting the negative interpretation. Fesko SEC filing Moshkevich SEC filing
• Negative Sentiment: The concentration of sales by the CEO, CFO and other insiders may nevertheless create modest short-term selling pressure or raise valuation concerns, particularly because NTRA remains well below its 52-week high and carries a negative trailing price-to-earnings ratio. However, the filings contain no new operational or financial warning.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 41,124 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. This represents a 27.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,405 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the completion of the sale, the insider owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This represents a 2.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 178,862 shares of company stock worth $40,416,335. 5.05% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Natera

Institutional investors have recently added to or reduced their stakes in the company. Reflection Asset Management purchased a new position in shares of Natera in the 4th quarter worth approximately $29,000. Elevation Wealth Partners LLC purchased a new stake in shares of Natera during the second quarter valued at approximately $30,000. Palladiem LLC purchased a new stake in shares of Natera during the fourth quarter valued at approximately $31,000. Horizon Investments LLC bought a new stake in Natera during the third quarter worth $32,000. Finally, International Assets Investment Management LLC lifted its holdings in Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares during the period. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.